Back

Serial transthyretin monitoring captures disease trajectory and predicts survival in cardiac amyloidosis

29 August 2026 (15:20 - 15:30)
Organised by: Logo
Congress Presentation Part of: Circulating and imaging biomarkers in heart failure Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Mounira Kharoubi

University Hospital Henri Mondor, Creteil (France)

5 More presentations in this session

Presentation thumbnail
Impact of circulating exosomal long non-coding RNA H19 on clinical outcomes in patients with heart failure
Doctor T. Koya (Sapporo, JP)
Abstract Slides Video
Presentation thumbnail
PEP/ET Ratio as a novel marker of subclinical heart failure and long term cardiovascular risk
Associate Professor T. Kabutoya (Shimotsuke, JP)
Abstract Slides Video
Presentation thumbnail
Real-time 3D shear wave elastography discriminates ATTR cardiac amyloidosis in patients with left ventricular hypertrophy
Doctor T. Meki (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Donor-derived cell-free DNA with clinical and echocardiographic data as independent predictors of Coronary Allograft Vasculopathy in heart-transplant recipients.
Doctor M. Calligaris (UDINE (UD), IT)
Abstract Slides Video
Presentation thumbnail
Heterogeneity biomarkers on cardiovascular magnetic resonance imaging – a novel paradigm to measure structural and functional variation in precision cardiology
Doctor K. Hesse (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Circulating and imaging biomarkers in heart failure
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 15:20 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center.
28 August 2020
thumbnail
Congress Session
What is the role of TTR in transthyretin amyloid cardiomyopathy?
2 September 2024
thumbnail
Congress Presentation
NT-proBNP and cardiopulmonary exercise testing parameters for risk stratification in ATTR-CM
5 April 2025
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources